OncoMatch/Clinical Trials/NCT07175220
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
Is NCT07175220 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including SHR2554; SHR-A2102 and SHR2554; Adabelimumab for locally advanced or metastatic non-small cell lung cancer.
Treatment: SHR2554; SHR-A2102 · SHR2554; Adabelimumab · SHR2554; SHR-1701 — Evaluate the safety, tolerability, and objective response rate (ORR) of SHR2554 tablets in combination with other anti-tumor treatments in subjects with locally advanced or metastatic non-small cell lung cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any anti-tumor treatment
Lab requirements
Blood counts
Has a good level of organ function
Kidney function
Has a good level of organ function
Liver function
Has a good level of organ function
Has a good level of organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify